Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Reluscovtogene Ralaplasmid · INO-4800, PGX-9501

Vaccine (DNA plasmid) · Immune activation, directed at SARS-CoV-2 spike protein · developed by INOVIO PHARMACEUTICALS

Phase 2/3 Most advanced trial (none active)

INO Developer

1 Registered trials

What is Reluscovtogene Ralaplasmid?

Reluscovtogene ralaplasmid is a DNA plasmid vaccine encoding the SARS-CoV-2 spike protein. Administered by intradermal injection with electroporation, it stimulates humoral and cellular immune responses against SARS-CoV-2. It is studied in COVID-19.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: INO-4800, PGX-9501
Drug type: Vaccine (DNA plasmid)
Targets: SARS-CoV-2 spike protein (antigen)
Mechanism: Immune activation, directed at SARS-CoV-2 spike protein
Pathways: humoral immune response, cellular immune response
Therapy area: Infectious disease
Developer: INOVIO PHARMACEUTICALS (INO)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII: 5Y0I0UU2IT

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04642638	Phase 2/3	Coronavirus Infection	Terminated	INO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Coronavirus InfectionCOVID-19 DiseaseSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

More from INOVIO PHARMACEUTICALS

DNA Plasmid-encoding Interleukin-12 INO-9012/PSA/PSMA DNA Plasmids INO-5150 Phase 1 INO-1400 Phase 1 INO-1401 Phase 1 INO-1800 Phase 1 INO-3106 Phase 1 INO-3107 Phase 1/2 INO-3401 Phase 1 INO-4201 Phase 1 INO-4202 Phase 1 INO-4212 Phase 1 INO-4500 Phase 1 INO-4700 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the INO page.

Follow INO, the company behind Reluscovtogene Ralaplasmid

See INO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INO catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z